Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Return on Invested Capital (2022 - 2025)

Amylyx Pharmaceuticals has reported Return on Invested Capital over the past 4 years, most recently at 0.13% for Q4 2025.

  • Quarterly results put Return on Invested Capital at 0.13% for Q4 2025, down 20.0% from a year ago — trailing twelve months through Dec 2025 was 0.13% (down 20.0% YoY), and the annual figure for FY2025 was 0.18%, down 22.0%.
  • Return on Invested Capital for Q4 2025 was 0.13% at Amylyx Pharmaceuticals, up from 0.63% in the prior quarter.
  • Over the last five years, Return on Invested Capital for AMLX hit a ceiling of 0.09% in Q4 2023 and a floor of 1.27% in Q1 2025.
  • Median Return on Invested Capital over the past 4 years was 0.25% (2022), compared with a mean of 0.45%.
  • Biggest five-year swings in Return on Invested Capital: crashed -116bps in 2024 and later soared 55bps in 2025.
  • Amylyx Pharmaceuticals' Return on Invested Capital stood at 0.25% in 2022, then surged by 136bps to 0.09% in 2023, then fell by -28bps to 0.06% in 2024, then plummeted by -309bps to 0.13% in 2025.
  • The last three reported values for Return on Invested Capital were 0.13% (Q4 2025), 0.63% (Q3 2025), and 1.07% (Q2 2025) per Business Quant data.